

In the Claims:

Please cancel claims 1-32 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a later-filed application and add new claims 33-42 as follows:

33. (New) A phosphorylatable antibody engineered to include at least one heterologous kinase recognition site located at a position other than a termini of the antibody such that an added phosphate group of a phosphorylated form of the antibody is protected from hydrolysis by intramolecular interactions with other amino acid residues so that at least 80% of all the phosphate groups remain attached after at least 5 days of incubation of the phosphorylated form in animal serum or buffer.
34. (New) The phosphorylatable antibody of claim 33, wherein the heterologous kinase recognition site is located at the carboxyl terminus of the antibody.
35. (New) The phosphorylatable antibody of claim 33, wherein at least 95% of all the phosphate groups remain attached after at least 5 days of incubation of the phosphorylated form in animal serum or buffer.
36. (New) The phosphorylatable antibody of claim 35, wherein at least 99% of all the phosphate groups remain attached after at least 5 days of incubation of the phosphorylated form in animal serum or buffer.
37. (New) The phosphorylatable antibody of claim 33, wherein the kinase recognition site is a recognition site for kinase which phosphorylates a serine, threonine or tyrosine residue.
38. (New) The phosphorylatable antibody of claim 33, wherein the kinase recognition site is a recognition site for a cyclic AMP dependent kinase, a cyclic GMP dependent kinase, or a cyclic nucleotide independent kinase

39. (New) The phosphorylatable antibody of claim 33, wherein the kinase recognition site is a recognition site for casein kinase I, casein kinase II, Src tyrosine kinase, mitogen-activated S6 kinase or rhodopsin kinase.

40. (New) The phosphorylatable antibody of claim 33, wherein the antibody is a monoclonal antibody.

41. (New) The phosphorylatable antibody of claim 40, wherein the monoclonal antibody is a humanized antibody, chimeric antibody, or hybrid antibody.

42. (New) The phosphorylatable antibody of claim 40, wherein the monoclonal antibody is a Fab fragment, Fab' fragment or an Fc fragment.